marketing teams

The window between Phase 3 and six months after drug product launch marks a pivotal time for pharmaceutical and biotechnology companies’ commercial efforts.  As products move through the pipeline, companies shift from market preparatory activities — such as...

By David Richardson, Research Team Leader Though no two pharmaceutical brands' commercialization strategies are exactly the same, the majority of companies follow similar spending patterns when launching new products. As brands move from early Phase...

By Casey Ferrell, Senior Research Analyst Our recent survey of pharma companies revealed that 58 percent have dedicated digital marketing groups. I think it’s safe to assume at this point that the digital revolution is real and is only going to continue...

By Michelle Vitko, Senior Research Analyst In an earlier blog post, I discussed the cost of patient non-adherence -- poorer health outcomes for patients and billions of dollars in lost product revenue. Low adherence rates have been a problem for a...

By Michelle Vitko, Research Analyst Drug companies are increasingly building centralized Patient Adherence teams, as revealed in our latest study on patient adherence. This is a recent development, with most companies reaching the decision to create...

By Michelle Vitko,Research Analyst The Research team is right in the middle of our new study of patient adherence and compliance, and we've now interviewed executives from a variety of companies in the life sciences industry about their patient adherence...

Pharmaceutical companies are looking to emerging markets to stimulate sales growth, especially in brands that have seen profits rapidly decelerate in established markets. But great success often comes with great struggles; and it certainly doesn't happen overnight....